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I must, however, raise one criticism.
I've noticed in the supplementary material (page 26) that by omitting from the meta-analysis the data of one of the ten trials (Gordon 2016) a statistically significant reduction in mortality would have been demonstrated for levosimendan.
Indeed Gordon 2016 was the larger of the ten trials and weighted for 42% (M-H) of the meta-analysis results, but it has been also the most criticized of the ten [1] [2] [3] [4] .
Despite Gordon 2016 was referred by the authors as having the least risk of bias (Page 21) of the ten selected studies, it was a multicenter trial in which the centers used very different therapy schemes for treating septic shock.
In clinical settings where there are local variations in therapeutic approaches and tailored strategies (such as, for example, septic shock) multicenter trials add, by definition, statistical noise to many endpoints: variations in pharmacologic and non-pharmacologic parameters have the potential to impair the statistical power and obscure meaningful effects. Such multicenter studies where multiple sources of heterogeneity exist (e.g. etiologies, comorbidities, comedications and center-specific treatment practices), encounter such problems.
Therefore, I recommend the authors of the present manuscript not to advocate the 'small-study effect', i.e. the trend for smaller studies to show larger treatment effects [5] , every study should be evaluated fairly independently of their size, as large studies can be imprecise and/or be based on wrong hypotheses, just as small ones can be precise [6] .
The authors should definitely comment in the main text and in the abstract the fact that, by excluding Gordon 2016, the results would be positive for levosimendan. 
REVIEWER
Anthony Gordon Imperial College London UK REVIEW RETURNED 19-Sep-2017
GENERAL COMMENTS
This manuscript by Chang and colleagues is a meta-analysis of the effect of levosimendan on mortality in sepsis. They report data on ~1000 patients from 10 RCTs and found no evidence of a reduction in mortality rates which contrasts with a previous smaller metaanalysis. Levosimendan's mechanism of action is interesting and has theoretical advantages compared to other inotropic agents. This updated information is therefore clinically important. The analysis is generally well conducted and reported. I do have some comments.
Major:
The PRISMA checklist is included which helps ensure robust reporting. However, was the protocol pre-registered anywhere? This is important to state, especially to clarify if the subgroups reported were pre-specified.
The analysis of the primary outcome demonstrated no significant reduction in mortality with levosimendan. I would suggest that the authors avoid adding the commentary "with a favouring direction towards levosimendan" in the abstract and line 40, page 8 and results section. The 95% CI clearly cross unity. Therefore, simply present the odds ratio and the 95%CI and allow the reader to interpret the result. This is particulary important as there is a suggestion of publication bias as the authors demonstrate in Supplement Fig 1. The secondary outcomes include many "clinical variables", eg serum lactate level, cardiac function, fluid infusion, vasopressor requirement (line 26 page 6). As these are repeated measures how was this analysis undertaken? Was it at a set timepoint or all values over time? Also it is not clear how the studies were included for this analysis. According to table study ref 28 (The LeoPARDS trial) was not included in any of these analyses but much of this data is provided in the published manuscript (including supplementary appendix). This data should be included.
I have some concern about the subgroup analyses (were they prespecified, see above?). Was a subgroup based on risk of bias planned? On page 8 bottom line, it states "patients were also divided according to…". This is not an individual patient data meta-analysis and therefore the patients weren't divided but the studies were divided. I am concerned by the split by age into subgroups as, apart from one trial, this was not a trial feature and most trials will have recruited adult patients of all ages. As the median age of sepsis trials is often ~65 years this seems like an arbitrary split and the play of chance of an average age in a trial cohort could randomly allocate a whole trial to a different subgroup. I don't think the age subgroup analysis is therefore meaningful. Furthermore, as all the subgroup interactions are not significant then the results should not be over interpreted. For this reason, in the abstract I would suggest deleting "…more severe patients (mortality >=50%) were more likely to benefit from levosimendan use…"
Minor comments:
The search strategy states it includes Simadax (page 5 and page 28). The correct spelling is Simdax. Did this typo miss any studies?
Were any attempts made to contact the authors of the 10 studies that didn't report mortality?
In the discussion (line 14, page 12) heterogeneity of ethnicity is mentioned for the first time as effecting the results but no data or rationale is provided. Please clarify?
Please provide more information about the imputation of missing data (line 54, page 6) 
REVIEWER

GENERAL COMMENTS
This work is a meta-analysis of randomized trials to evaluate the effect of levosimandan on mortality in severe sepsis and septic shock.
Major comments :
1) The main issue of this work is the choice of the primary outcome : Mortality at the longest follow-up. The follow-up of patients are different among the selected studies. We have no idea of the amount of heterogeneity introduced by this choice. Authors should precise at what time point the mortalities were registred in each study. Merging results for example of 1 week mortality, 90 days mortality, 1 year mortality, ICU mortality or hospital mortality has no sense. Selection of studies should also considered this criteria. And it should be given in the article.
2) Authors should be more precise in the definition of their secondary endpoints (in the methods section) and simultaneously be more precise on which methods are used for complex outcomes (in the statistical subsection). Indeed, length of stay (LOS) is a very difficult outcome to handle. Usually, median should be given in articles (and not mean and SD) and basic random effect models (i.e. based on Gaussian distributions) are not well adapted for that kind of right censored and skewed distributions. Authors should explain clearly which models are used for those outcomes.
3) We have no complete description off all the outcomes considered for the « cardiac function ». We only have informations about some measurements "included" to evaluate the cardiac function.
4) I'm worried about the impact of the Gordon Study on the results.
Without this study, the meta-analysis would be largely in favor of the of the levosimandan. I would like a deeper discussion on that point. I don't subscribe to their remarks on alpha risk. If analyses are well performed the sample size should not impact the alpha risk, only the power of the study should be impacted. Rather than those vague considerations on statistics, authors should try to understand and explain the heterogeneity of this study compare to others (even if the I^2 is not significant).
5)
Concerning the sub-group analyses, they are mentioned only in the results section. Authors should clearly state if those analyses were post-hoc or pre-specified in the statistical plan of the metaanalysis.
6) The limitations section is too general. One more time, authors should precise what kind of heterogeneities are observed. They can not just assess that there is heterogeneity without be more sharp on this heterogeneity.
Minor comments :
1) The PRISMA checklist has been performed. Perhaps, the line given in supplementary file 1 (about the complete search strategy) could be directly given in the paper.
VERSION 1 -AUTHOR RESPONSE
Response to the Editorial Team: Dear Editorial Team, Thanks very much for reviewing my manuscript and we appreciate for all the comments, advices and criticism from all the reviewers which is a great help for the further polishing and improving this manuscript.
We have further reviewed relevant literatures on the use of levosimendan and septic cardiomyopathy.
We thought that the main reasons of the particularities of the trial by Gordon et al are as follows, (which was also mentioned in our manuscript, discussion section): 1. The percentage of patients in that study who underwent cardiac function assessment was rather low (30%), so Gordon and co-workers might have enrolled the patients with heterogenous cardiac function [1, 2] . Although the prevalence of septic cardiomyopathy is high (40-60%) [3] , but the discriminative enrollment could still obscure the potential benefit of levosimendan in sepsis, considering that there are patients recruited who did not have cardiac dysfunction, and may not benefit from inotropic use as indicated by the SSC (2016) Guideline in which the increase of cardiac function to supranormal level is discouraged [4] . We attempted to synthesized the studies in which the patients had definite cardiac dysfunction, however the result revealed no statistical significance (OR 0.76, 95% CI 0.39-1.50, P = 0.43). We then ran a trial sequential analysis (TSA) and yielded an optimal sample size of 1719, suggesting more trials are needed focusing on the patients with cardiac dysfunction for the plausible effects of levosimendan in sepsis.
2. The patients enrolled in the trial by Gordon et al. might be relatively at low risk [1, 2] . Although the 28-day mortality in that trial was 31%, which was markedly high. However, according to previous studies, the mortality decreased from 61% to 47% after levosimendan use [5] . It should be noted that the baseline mortality is very high (61% in control group), suggesting that the patients at "extremely" high risk may be most benefited from levosimendan use.
We also attempted to synthesized the studies dividing the studies with patients at high (≥ 50%) and low (< 50%) risks and found with OR 0.55, 95% 0.30-1.03 vs. OR 0.89, 95% 0.69-1.16, respectively. Although no statistical significance could not be observed, we found the group of studies with highrisk patients were more likely to benefit from levosimendan use, still, more trials are definitely needed. There are some other comments on the trials by Gordon et al. including that the patients included were not sufficiently resuscitated, the dose regimen of levosimendan was too high (0.2μ/kg per min) and the long lag time (about 15 hours) of patients' admission and recruitment [1] . However, these could also occur in other trials or were unknown in other trials included and we thought were beyond the scope of this discussion. We thought that the new information of our study added to the current knowledge would be the quantitative analysis of the effect of levosimendan on mortality in sepsis, and to find the potential subgroup that would possibly benefit most from levosimendan use, and also the clues why the results of the trial by Gordon et al. differed from others. Even now, the effects of dobutamine on mortality in sepsis was still controversial and regarded neutral or no-harm [4] , so we thought that the effect levosimendan could also possibly be insignificant. However, the rational trial design including patients' selection, grouping, dose regimen is prerequisite to testify this. We've made some modifications to the original manuscript except from the grammar and the expressions. The main modifications are listed as follows: ABSTRACT section 1. We deleted the statement of "…at the longest follow-up…" and tailored the follow-up at the proximal durations. (advised by Prof. Resche-Rigon) 2. We deleted the description of results of sub-group analysis by average age and mortality, since the evidence was not solid enough to draw the conclusion. We admitted that multi-center study could possibly bring heterogeneity between each center, which could not be avoided, but still, the trial by Gordon et al. was least biased among the studies we included in this meta-analysis, and we thought that, apart from background noises, there may be other reasons for the negative results (as mentioned above). 1. As pointed out by many, the percentage of patients in that study who underwent cardiac function assessment was rather low (30%), so Gordon and co-workers might have enrolled the patients with heterogenous cardiac function [1] . Although the prevalence of septic cardiomyopathy is high (40-60%) [2] , but the discriminative enrollment could still obscure the potential benefit of levosimendan in sepsis, considering that there are still patients who did not have cardiac dysfunction, and may not benefit from inotropic use as indicated by the SSC (2016) Guideline in which the increase of cardiac function to supranormal level is discouraged [3] . We attempted to synthesized the studies in which the patients had definite cardiac dysfunction, however the result revealed no statistical significance (OR 0.76, 95% CI 0.39-1.50, P = 0.43). We then ran a trial sequential analysis (TSA) and yielded an optimal sample size of 1719, suggesting more trials are needed focusing on the patients with cardiac dysfunction for the plausi ble effects of levosimendan in sepsis. 2. The patients enrolled in the trial by Gordon et al. might be relatively at low risk. Although the 28-day mortality in that trial was 31%, which was markedly high. However, according to previous studies, the mortality decreased from 60% to 48% after levosimendan use [4] . It should be noted that the baseline mortality is very high (60% in control group), suggesting that the patients at "extremely" high risk may be most benefited from levosimendan use. We also attempted to synthesized the studies dividing the studies with patients at high (≥ 50%) and low (< 50%) risks and found with OR 0.55, 95% 0.30-1.03 vs. OR 0.89, 95% 0.69-1.16, respectively. Although no statistical significance could not be observed, we found the group of studies with highrisk patients were more likely to benefit from levosimendan use, still, more trials are definitely needed. Also, we deleted the statement of "small-study effect", since we thought we should analyze the reason why the positive results obscured, while not just consider it as a statistical issue. We focused the particularities of the trial by Gordon et al. in the discussion section, and we thought it inappropriate to single out one trial in the abstract, so we did not mention it in the abstract. Thank you very much for your time and consideration. Best Regards. Sincerely, Chang, Wei with all the co-workers
Response to Reviewer 2 Dear Prof. Gordon, Thank you very much for reviewing our manuscript. We are honored to have your work included in our meta-analysis and much appreciated for your comments and advices, which is a great help to improve our study. 1. Unfortunately, we did not register our protocol during the time we prepared this manuscript, but we strictly follow the PRISMA instructions. This meta-analysis is now being retrospectively registered in PROSPERO, and is being assessed by the editorial team. 2. All the subgroups are pre-specified, we add a "sub-analysis" title to the METHODS part to further elucidate the methods we dividing the studies. 3. We fully agreed that the statement of "…with a favouring direction towards levosimendan" was inappropriate here, thus we deleted this narrative and let the reader interpret the results by themselves. 4. We reviewed all the studies included and found that most of studies compared the measurements of lactate, cardiac function (including cardiac index, left ventricular ejection fraction, left ventricular stroke work index), fluid infusion and norepinephrine regimen at the end of levosimendan infusion (24 hour). We included the data of the trial by Gordon et al., and we noticed that some of the measurements were taken in multiple times, and the measurement at 24-hour was taken into our meta-analysis. 5. We've attempted to conduct a sub-group analysis based on bias, unfortunately, other studies we included were at moderate to high risks of bias compared with the work of Gordon et al, and still no statistical significance could be observed after the synthesis, and we did not ment ion it in our main text. 6. We realized that the narrative of "…patients were divided…" was not accurate and we corrected all such narratives to "…studies were divided according to the enrolling patients…" 7. We debated fiercely when conducting the sub-group analyses according to the patients' age and mortality, some authors argued that such grouping was too arbitrary and made no sense. We now tone down the interpretation of this sub-group analysis, and removed the statement of "Younger patients … statistical significance." from the abstract since we thought that the evidence was not solid enough to draw the conclusion. We removed the forest plots of these two sub-group analyses from the main text, and provided these as supplementary figures. We were hoping to find the potential optimal sub-population that would possibly benefit from levosimendan use, based on current resources. 8. We reviewed the search history and found the original key word we used was "Simdax", so this typo occurred when preparing this manuscript, thus no studies were missed. 9. We are sorry that we did not contact the authors in ten studies that the mortality was not reported. 10. In the original version of manuscript we attempted to divide the studies by countries within which three studies were conducted in China with Asian participants, however, as no statistical significance was found, we delete this part in discussion section. We've deleted the "ethnicity" in the main text. 11. The imputation of missing data was partly referred to the methods by Wiebe et al [6] , and we provided a supplementary file in detailed description the methods we imputing the missing data. Thank you very much for your time and consideration. Best Regards, Sincerely, Chang, Wei, with all the co-workers
Response to Reviewer 3 Dear Prof. Resche-Rigon, Thanks very much for reviewing our manuscript and we much appreciated your comments, suggestions and criticisms. 1. We fully agreed that the comparison of mortality with different follow-up days was absolutely inappropriate. Thus, we reviewed the studies we included and found that in one study (Memis D, 2012), follow-up day was not reported; in two studies (Alhashemi JA, 2009; Morelli A, 2010), only the ICU mortalities were reported; and in other studies follow-up day ranged from 28-30 days, within which, the "longest follow-up days" were originally used as end-point in two studies (Gordon AC, 2016; Wang X, 2017). Now we've tailored the follow-up day in these two studies to day 28, although no shifts in results, we thought this method is more reasonable. We further ran an analysis with studies with arbitrary follow-up days eliminated (Alhashemi JA, 2009; Memis D, 2012; Morelli A, 2010), with no changes in results of mortality. We also agreed that the length of ICU stay (LOS) is not easy to handle and could potentially bring heterogeneity to the results, but as the most studies reported the LOS, we then synthesize the results, maybe it bring some clues to the clinical practice. 2. We agreed that the description in the METHODS section was not clearly elucidated. We thereafter described the in detail the statistical method we used for each outcome. To be honest, not all the data were strictly normal distributed and were presented as median (IQR). As the original data was not possibly obtained and transformed for better adaption, as mean and standard deviation were required for meta-analysis, missing data were imputed which we described in a supplementary file. Randomeffects model was applied for all the analyses for better accommodation of the heterogeneity between studies (I2 statistics was as high as 90% in some sub-group analyses). 3. We extracted and synthesized the measurements (CI, LVEF and LVSWI) reflecting cardiac function and found that the CI, LVEF and LVSWI were all increased in levosimendan, thus we thought that the cardiac function was improved in levosimendan group, as we indicated in the main text. 4. We further discussed the impact of study by Gordon et al. especially why the clinical significan ce obscured after its entry in our discussion section. We thought that the main reasons were as follows (as mentioned above, and also in our discussion section): 1) As pointed out by many, the percentage of patients in that study who underwent cardiac function assessment was rather low (30%), so Gordon and co-workers might have enrolled the patients with heterogenous cardiac function [1] . Although the prevalence of septic cardiomyopathy is high (40-60%) [2] , but the discriminative enrollment could still obsc ure the potential benefit of levosimendan in sepsis, considering that there are still patients who did not have cardiac dysfunction, and may not benefit from inotropic use as indicated by the SSC (2016) Guideline in which the increase of cardiac function to supranormal level is discouraged [3] .
2) The patients enrolled in the trial by Gordon et al. might be relatively at low risk. Although the 28-day mortality in that trial was 31%, which was markedly high. However, according to previous studies, the mortality decreased from 60% to 48% after levosimendan use [4] . It should be noted that the baseline mortality is very high (60% in control group), suggesting that the patients at "extremely" high risk may be most benefited from levosimendan use. 5. All the sub-group analyses were pre-specified and we add the "Sub-group analysis" title in our METHODS section. 6. We fully agreed that the general narrative offered no information but confusion to the readers, thus we pointed out explicitly the potential sources of the heterogeneity in the limitation section, including that 8 out 10 studies included less than 50 participants, the follow-up duration was not consistent and the dose regiment varied. 2) Authors claim in their response that "All the sub-group analyses were pre-specified". Please precise this point in the revised manuscript too.
3) I don't understand why the results of the table 2 are not the same between the 2 versions of the manuscript.
VERSION 2 -AUTHOR RESPONSE
Reply to Editorial Office
Dear Editor, Thanks very much for reviewing our manuscript and we are appreciate for your valuable comments and criticisms.
In this version, we went through the main text and corrected the typographical and grammatical errors. We also consulted a native English speaker, with whose help, we corrected some inappropriate expressions. We sincerely hope that the language of this version would be improved.
The comments by the reviewers were also replied. We improved our calculation and analyses, and added some of the missing data for the completeness of the calculation. We deleted the synthesized results of the length of ICU stay (LOS), since it was not accurately and appropriated analyzed and presented.
Some of the figures were also improved and up-loaded.
We thank very much for all the considerations, comments and criticisms from the editorial office and all the reviewers, it's a great help for us to improve our work and for our future study.
Best regards, Sincerely,
Chang, Wei with all the co-workers.
Reply to Reviewer 1 Dear Prof. Pollesello, Thank you very much for your comments and criticism, it is a great help for us to improve this work and also for further investigations.
Best regards, Sincerely, Chang, Wei, with all the co-workers.
Reply to Reviewer 2 Dear Prof. Gordon, Thank you very much for your comments and criticism.
We scrutinized our original data and recalculated the SD for the changes in the secondary outcomes in Suppl Fig 2.2 and 4 , and recognized the mistake in calculation. We've corrected all the mistakes, re-calculated all the outcomes, and up-loaded the corrected figures.
The data of norepinephrine was also calculated and included in the figure and table.
Best regards,
Sincerely,
Chang, Wei, with all the co-workers.
Reply to Reviewer 2
Dear Prof. Resche-Rigon, Thank you very much for your comments and criticism.
We discussed the results of LOS again and we thought it better not to present it in our manuscript, thus we removed the contents pertaining the results of LOS. We thought it inappropriate to present the result which was not calculated and analyzed accurately enough. We also read the article by Wan X et al, and re-checked the data we extracted and transformed in our manuscript. We thought it a great help for our current and future work.
We added the sentence "The sub-group analyses were pre-specified" in method section explicitly to describe the methodology.
As for the question that why the results in Table 2 was different in the two versions, we re-checked the studies included, and extracted more data from the supplementary material in the 2nd version. We subsequently added the data in the calculation and updated the results, and there are still some updates in the results in this version due to revision of calculations.
Best regards, Sincerely, Chang, Wei, with all the co-workers. 
